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The Analytical Research and Development Department of
Bristol-Myers Squibb has a laboratory dedicated to robotic analysis
of solid doseforms. It consists of eight individuals responsiblefor
191
nine robotic systems. The laboratory is dedicated to the support of
Phase III stability studies that require dissolution, potency, content.
uniformity and Karl Fischer moisture assays. The group performs
about 15000 assays ayearfor approximately six long-term stability 92
programs. The key issues for success were personnel selection,
methods development (methods transfer), routine assay support,
documentation, validation, training and support services. This
paper discusses the establishment of the laboratory and the future 3
issues important to continued success.
Phase III Stability
Introduction
The Analytical Research & Development Department
of the Bristol-Myers Squibb (BMS) Pharmaceutical
Research Institute has developed a robotics laboratory to
provide automated assay support of its Phase III clinical
and stability programes within pharmaceutical develop-
ment.
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The typical assays within pharmaceutical analysis that
constitute the majority of the work in a Phase Ill stability
programme are:
(1) Potency/degradants.
(2) Dissolution.
(3) Karl Fischer moisture.
The routine Phase III sample load can often exceed the
resources available within the non-automated laboratory
and the robotics laboratory at BMS has been designed to
provide automated support for each of these assays.
The robotics laboratory houses nine robots, two
workstations and has a staff of eight (including the
laboratory manager). The majority of the robots are
dissolution due to the labour intensive nature of
this assay, while the remainder are predominantly tablet
assay robots or workstations. One robot is used for all
Karl Fischer moisture determinations. The laboratory
includes:
(1) Nine Robots (Zymark Corporation): five dissolution;
three tablet assay; and one Karl Fischer Titration..
This paper was presented at the 1993 International Symposium on
Laboratory Automation and Robotics (ISLAR) organized by the
Zymark Corporation.
(2) Two workstations: BenchMate (Zymark Corporation);
and SmartPREP (Source for Automation).
(3) Personnel: four system managers; and three chemical
technicians.
A history of the productivity of the laboratory over the
past three years is provided in figure 1. The laboratory
assayed over 15 000 samples in 1991 ofwhich the majority
were dissolution assays. The totals have decreased steadily
over the past two years due to the reduced sample loads for
older Phase III programmes and the lack of new Phase
III programmes that were started during this time. The
15 000 samples assayed in 1991 represent less than 50%
of the laboratory’s capacity, and there is significant room
for expansion.
Key issues for success
Before discussing the key issues necessary for success in
developing a robotics laboratory, it is instructive to review
some of the inherent obstacles to success. Several obstacles
are presented in table that are worth mentioning here.
The first two acknowledge the high cost and demand on
resources that an automated laboratory requires,
especially during the initial phase. This inevitably leads
to special needs for education of the users or system
managers for each robotic system. Furthermore, the
complexity of robotic systems for total automation of the
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Table 1. Inherent Obstacles to success.
High cost
High demand for resources
User education
Complexity
Long automation design cycle
GLP/GMP requirements
Table 2. Key issuesfor success.
Personnel selection
Methods development
Routine assay s.upport
Training
Documentation/validation
Support services
typical assays can lead to extended design cycles. Rarely
is success achieved immediately upon installation. Finally,
a special requirement particular to the Pharmaceutical
Industry is the need for adherence to current Good
Laboratory Practices (GLP) and Good Manufacturing
Practices (GMP) regulations within the operating
laboratories.
The key issues for success are shown in table 2. The
assumption here is that management support and
adequate funding and facilities are available for the
laboratory.
The most important factor is personnel selection. Many
obstacles or inadequate support in the other areas listed
in table can be overcome by a creative and highly
motivated staff. The ideal candidate has strong analytical
skills, is computer literate and is detail oriented.
Understanding the key steps in an analytical method is
essential to its successful automation. Successful auto-
mation chemists are also part engineer (both mechanical
and software) since they pertbrm the translation of the
manual procedure into an automated one to be performed
by a blind, deafand dumb robot. This can be a frustrating
experience that requires perserverance, creativity and a
willingness to experiment and question assumptions.
However, perfictionist tendencies can be t;atal because at
some point development steps and routine samples need
to be run.
A key area for success in assay support is methods
development. Experience has taught BMS to follow an
experimental plan that has developed over time for each
assay type that is automated. Initially, this did not exist
as experience was gained about the importance of certain
assay requirements. For automation ofmanual dissolution
assays, the appropriateness of the method for use on the
robot is assessed and, if suitable, the validation plan is
developed to transfer the assay. This allows templates to
be built which are followed during method development
and speeds the whole process to completion. This is
particularly important for stability assays where it is
necessary to make the transition from development to
heavy support for routine assays very quickly and
smoothly. It is critical to develop efficient procedures for
handling sample and data management very early in the
development cycle. This is necessary to avoid the classic
automation bottleneck that occurs when robots stand idle
while results are calculated and notebook entries are
completed.
A tedious and time-consuming task that can be viewed
as unproductive is the GLP/GMP validation and
documentation of a system. The documentation is
comprised of a considerable volume of paper on the
hardware and software that constitutes a robotic system.
This is not provided with most installations and must
be prepared by the user. Validation requires an
understanding of the key procedures or processes under
the control of the robot that must be tested to ensure
accuracy, suitability and adherence to any GMP
requirements. This may be as simple as validating the
determination of the vessel temperature in a dissolution
test that must meet USP criteria. Since it is only
recently that this information can be provided by
the manufacturer, the users generally decided what
documentation was necessary. Furtheremore, provisions
for system security and software change control need to
be addressed as a part of computer system validation.
Technical support services are needed both from the
vendor and in-house to adequately service, maintain and
integrate the robotic system within the data management
systems of the development. Robots that perform LC
injections can create a heavy workload for a chromato-
graphic data processing system; it is a key requirement to
have sufficient capacity for each robot. Furthermore,
development of custom assay methodologies may require
engineering services, such as mechnical or electrical to
develop custom hardware for each application. Once
again, this is a labour intensive and iterative process.
Future plans
BMS has shifted from late stage development projects with
heavy Phase III support requirements to early stage
projects that have vastly different dynamics than Phase
III programmes. Experiences with Phase III programs
has provided a substantial amount of information
about methods development strategies and sample/data
management for high-load projects. However, to
participate and contribute to early stage development
projects, it is important to be flexible and expand the
laboratory’s capabilities. For example, early stage
development dose forms are typically dry-filled capsules
that pose different challenges for dissolution and potency
assays than tablets. It is necessary to rely on our methods
development strategies to respond quickly and continue
to expand the laboratory’s technological capability to
assay dry-filled capsules. Furthermore, it demands more
of the laboratory’s analytical capabilities, since less is
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known about the compound and dose form behavior. The
ability to automate at an early stage will be a bonus if the
project moves to the latter stages of development, since a
robot-friendly analytical method is available.
Acknowledgements
The author would like to thank the following tbr
their valuable contributions to the success of this
project. Current and past management ofARD including:
Drs Berry J. Kline, Glenn A. Brewer and Jerry R. Allison.
The current members of the robotics laboratory
team: Dan Barrow, Scott Jennings, Rich Vol Culin,
John Rumney, Jim Wysocki, Alma Johnson and Khanh
Ha.
119